组织陈列-产品详情

home > TISSUE ARRAYS > Liver > DLV1502

Type
- FFPE
- FROZEN TISSUE
Identity
Organ
- Liver
- Esophagus
- Ovary
- Stomach
- Lung
- Colon
- Rectum
- Kidney
- Breast
- Endometrium
- Uterus
- Bladder
- Pancreas
- Skin
- Penis
- Testis
- Soft_Tissue
- Bone/Cartilage
- Oral/Cavity
- Bone/Marrow
- Heart
- Spleen
- Head/Neck
- Vulva
- Melanoma
- Appendix
- Intestine
- Adrenal Gland
- Thymus
- Fallopian tube
- Mouse
- Fetus
- Rat
- Monkey (Rhesus) (Normal)-RsFPT
- Monkey (Cynomolgus) (Normal)-CyFPT
- Dog
- Multiple organ
- Gall bladder and bile duct
- Esophagogastric junction
Types/Disease
Cores
Cases

Cores:

150

CASES:

75

Core Diameter(mm):

1

Thickness(µm):

5

Row number:

10

Column number:

15

Tissue Array Type:

FFPE

Species:

Human

DLV1502

$215.00

Add To Collect

Description: Liver cancer tissue array, including pathology grade, TNM and clinical stage, 75 cases/150 cores

Details: Hepatocellular carcinoma tissue microarray, containing 60 cases of hepatocellular carcinoma, 10 cholangiocarcinoma, 3 cirrhosis and 2 normal liver tissue, duplicate cores per case (duplicate cores from the same patient were put onto two rows in the same position)

Applications: Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page

Please Select Tissue Array Type:

Unstained

H&E

Tag:

Add To Cart

Outright purchase

Note

1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning.
2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.
In the following specsheet,“*” means invalid core; “-” means no applicable or negative in IHC markers."

Specification sheet
Overlapping case
Download specifications

Legend:

Car-Cardia Eso-Fsophagus

Cirrhosis(*)
Normal(*)
Malignant(IB)
Malignant(II)
Malignant(IIIA)
Malignant(IIIB)
Malignant(IVA)
_ma

TISSUE ARRAYS
DLV1502

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
A	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
B	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
C	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
D	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
E	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
F	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
G	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
H	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
I	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
J	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	_ma

DLV1502

Age:
Sex:
Organ/Anatomic Site:
Pathology diagnosis:
Grade:
TNM:
Stage:
Tissue ID.:
Type:

Pos	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	Grade	TNM	Stage	Type	Tumor size	Ki-67	CK18
A1	1	52	M	Liver	Hepatocellular carcinoma with necrosis	1	T3N0M0	IIIA	Malignant	1495.5	-	+,10%
A2	2	45	M	Liver	Hepatocellular carcinoma	1	T2N0M0	II	Malignant	5.04.04.0	-	+++,100%
A3	3	41	M	Liver	Hepatocellular carcinoma	1	T2N0M0	II	Malignant	6.05.04.0	-	+,90%
A4	4	69	M	Liver	Hepatocellular carcinoma	1--2	T3aN0M0	IIIA	Malignant	1299	-	+,70%
A5	5	36	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	857	-	+,50%
A6	6	72	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	5.55.03.5	-	++,100%
A7	7	49	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	1032.5	-	++,100%
A8	8	43	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	*	+,1%	+,90%
A9	9	40	M	Liver	Hepatocellular carcinoma	2	T3N1M0	IVA	Malignant	5	-	++,90%
A10	10	77	M	Liver	Hepatocellular carcinoma	2	T3aN0M0	IIIA	Malignant	6.05.05.0	*	+,30%
A11	11	63	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	4.03.52.5	*	+,30%
A12	12	51	M	Liver	Hepatocellular carcinoma	2	T3aN1M0	IVA	Malignant	6	+,2%	+,40%
A13	13	56	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	644	-	++,100%
A14	14	48	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	*	-	-
A15	15	53	F	Liver	Hepatocellular carcinoma	2	T1bN0M0	IB	Malignant	643	-	+,90%
B1	16	52	M	Liver	Hepatocellular carcinoma with necrosis	1	T3N0M0	IIIA	Malignant	1495.5	-	+,10%
B2	17	45	M	Liver	Hepatocellular carcinoma	1	T2N0M0	II	Malignant	5.04.04.0	-	+++,100%
B3	18	41	M	Liver	Hepatocellular carcinoma	1	T2N0M0	II	Malignant	6.05.04.0	-	+,90%
B4	19	69	M	Liver	Hepatocellular carcinoma	1--2	T3aN0M0	IIIA	Malignant	1299	-	+,80%
B5	20	36	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	857	-	+,60%
B6	21	72	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	5.55.03.5	-	++,70%
B7	22	49	M	Liver	Hepatocellular carcinoma with necrosis	2	T2N0M0	II	Malignant	*	-	++,60%
B8	23	43	M	Liver	Hepatocellular carcinoma (sparse)	2	T2N0M0	II	Malignant	*	+,2%	+,30%
B9	24	40	M	Liver	Hepatocellular carcinoma	2	T3N1M0	IVA	Malignant	5	-	++,90%
B10	25	77	M	Liver	Hepatocellular carcinoma	2	T3aN0M0	IIIA	Malignant	6.05.05.0	-	+,30%
B11	26	63	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	4.03.52.5	-	+,30%
B12	27	51	M	Liver	Hepatocellular carcinoma	2	T3aN1M0	IVA	Malignant	6	-	+,70%
B13	28	56	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	644	-	++,100%
B14	29	48	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	*	+,2%	+,30%
B15	30	53	F	Liver	Hepatocellular carcinoma	2	T1bN0M0	IB	Malignant	2	-	++,80%
C1	31	37	M	Liver	Hepatocellular carcinoma with necrosis	2	T3N0M0	IIIA	Malignant	4.54.03.5	+,3%	++,60%
C2	32	60	M	Liver	Hepatocellular carcinoma	2	T3aN0M0	IIIA	Malignant	6.55.03.5	+,3%	+++,100%
C3	33	49	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	422	-	+,10%
C4	34	45	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	4.53.03.0	-	+,90%
C5	35	57	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	6.55.03.5	-	+++,100%
C6	36	32	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	543	-	+,80%
C7	37	40	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	8*4	-	+,80%
C8	38	58	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	*	-	+,80%
C9	39	63	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	*	-	+,30%
C10	40	48	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	654	-	++,100%
C11	41	62	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	753	+,5%	+,40%
C12	42	74	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	6*5	-	+,20%
C13	43	50	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	4*3	-	++,60%
C14	44	24	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	542.5	-	+++,100%
C15	45	58	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	776	+,5%	++,70%
D1	46	37	M	Liver	Hepatocellular carcinoma with necrosis	2	T3N0M0	IIIA	Malignant	4.54.03.5	+,10%	++,60%
D2	47	60	M	Liver	Hepatocellular carcinoma	2	T3aN0M0	IIIA	Malignant	6.55.03.5	+,5%	+++,100%
D3	48	49	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	422	+,1%	+,10%
D4	49	45	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	4.53.03.0	+,1%	+,90%
D5	50	57	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	6.55.03.5	+,2%	+++,100%
D6	51	32	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	543	-	++,70%
D7	52	40	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	8*4	-	+,80%
D8	53	58	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	*	+,5%	+,80%
D9	54	63	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	*	-	+,60%
D10	55	48	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	654	-	++,100%
D11	56	62	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	753	+,5%	+,40%
D12	57	74	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	6*5	-	+,20%
D13	58	50	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	4*3	-	+,40%
D14	59	24	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	542.5	-	+++,100%
D15	60	58	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	776	+,5%	++,70%
E1	61	63	F	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	7	+,5%	+,60%
E2	62	51	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	3.5	-	+,10%
E3	63	54	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	6.55.03.0	-	++,80%
E4	64	60	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	4*4	-	+,10%
E5	65	58	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	5.54.02.0	+,4%	+,10%
E6	66	53	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	6.05.04.0	+,15%	+++,100%
E7	67	57	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	4.5*3.5	-	+,30%
E8	68	62	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	3	-	++,70%
E9	69	50	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	5*3	+,5%	++,90%
E10	70	50	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	*	-	+,10%
E11	71	62	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	6.04.03.0	++,10%	++,70%
E12	72	41	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	*	+,10%	+,60%
E13	73	61	F	Liver	Hepatocellular carcinoma	2	T3N1M0	IVA	Malignant	7	+,1%	+,80%
E14	74	47	M	Liver	Hepatocellular carcinoma	2--3	T3N0M0	IIIA	Malignant	8.56.03.5	-	+,60%
E15	75	42	M	Liver	Hepatocellular carcinoma with necrosis	2--3	T2N0M0	II	Malignant	5.05.03.5	-	++,100%
F1	76	63	F	Liver	Hepatocellular carcinoma with necrosis	2	T3N0M0	IIIA	Malignant	7	+,5%	+,60%
F2	77	51	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	3.5	-	+,10%
F3	78	54	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	6.55.03.0	-	++,80%
F4	79	60	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	4*4	-	+,10%
F5	80	58	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	5.54.02.0	+,5%	++,60%
F6	81	53	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	6.05.04.0	+,15%	+++,90%
F7	82	57	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	4.5*3.5	-	+,20%
F8	83	62	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	3	-	+,60%
F9	84	50	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	5*3	+,5%	++,90%
F10	85	50	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	*	-	+,10%
F11	86	62	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	6.04.03.0	+,10%	++,80%
F12	87	41	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	*	+,15%	+,70%
F13	88	61	F	Liver	Hepatocellular carcinoma	2	T3N1M0	IVA	Malignant	7	-	+,80%
F14	89	47	M	Liver	Hepatocellular carcinoma	2--3	T3N0M0	IIIA	Malignant	8.56.03.5	-	+,60%
F15	90	42	M	Liver	Hepatocellular carcinoma	2--3	T2N0M0	II	Malignant	5.05.03.5	-	++,100%
G1	91	63	M	Liver	Hepatocellular carcinoma (degeneration)	*	T3N0M0	IIIA	Malignant	6.55.03.5	-	+,80%
G2	92	51	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	*	+,15%	++,80%
G3	93	52	F	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	6.04.54.5	+,15%	+,50%
G4	94	60	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	8.075	-	++,40%
G5	95	38	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	15.5124	+,5%	++,60%
G6	96	27	F	Liver	Hepatocellular carcinoma	3	T4N0M0	IIIB	Malignant	*	-	-
G7	97	41	M	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	*	-	+++,90%
G8	98	57	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	1764	-	+,50%
G9	99	45	M	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	*	-	-
G10	100	47	M	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	3.52.52.2	-	++,80%
G11	101	49	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	655	-	++,80%
G12	102	62	M	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	*	+,5%	++,90%
G13	103	60	F	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	765	+,15%	+,80%
G14	104	65	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	7*6	-	++,80%
G15	105	51	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	965	-	+,40%
H1	106	63	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	6.55.03.5	-	+,80%
H2	107	51	M	Liver	Hepatocellular carcinoma with necrosis	3	T3N0M0	IIIA	Malignant	*	+,5%	++,80%
H3	108	52	F	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	6.04.54.5	+,15%	+,20%
H4	109	60	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	8.075	-	++,80%
H5	110	38	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	15.5124	+,5%	++,60%
H6	111	27	F	Liver	Hepatocellular carcinoma	3	T4N0M0	IIIB	Malignant	*	-	-
H7	112	41	M	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	*	+,1%	+++,90%
H8	113	57	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	1764	-	+,50%
H9	114	45	M	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	*	-	-
H10	115	47	M	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	3.52.52.2	-	++,80%
H11	116	49	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	655	-	++,80%
H12	117	62	M	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	*	+,5%	++,80%
H13	118	60	F	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	765	++,15%	+,30%
H14	119	65	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	7*6	-	+++,100%
H15	120	51	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	965	-	+,40%
I1	121	50	F	Liver	Cholangiocarcinoma	2	T3N1M0	IVA	Malignant	5	-	++,80%
I2	122	52	F	Liver	Cholangiocarcinoma	2	T3N1M0	IVA	Malignant	6.5	+,5%	+,70%
I3	123	62	M	Liver	Cholangiocarcinoma with necrosis	2--3	T2aN0M0	II	Malignant	6	++,20%	++,90%
I4	124	60	F	Liver	Cholangiocarcinoma	2--3	T3N0M0	IIIA	Malignant	7	-	++,70%
I5	125	64	M	Liver	Cholangiocarcinoma	3	T3N1M0	IVA	Malignant	9	-	+,30%
I6	126	68	M	Liver	Cholangiocarcinoma	3	T3N0M0	IIIA	Malignant	5	++,50%	+++,90%
I7	127	68	M	Liver	Cholangiocarcinoma with necrosis	3	T3N0M0	IIIA	Malignant	7	+,5%	+,15%
I8	128	65	M	Liver	Cholangiocarcinoma	3	T3N0M0	IIIA	Malignant	7	-	+++,100%
I9	129	57	M	Liver	Cholangiocarcinoma	3	T3N0M0	IIIA	Malignant	9	-	++,60%
I10	130	51	M	Liver	Cholangiocarcinoma (degeneration)	*	T3N1M0	IVA	Malignant	*	*	*
I11	131	53	M	Liver	Cirrhosis	*	*	*	Cirrhosis	*	-	+,20%
I12	132	59	M	Liver	Cirrhosis	*	*	*	Cirrhosis	*	-	++,80%
I13	133	45	M	Liver	Cirrhosis	*	*	*	Cirrhosis	*	+,3%	++,80%
I14	134	23	M	Liver	Liver tissue	*	*	*	Normal	*	-	++,100%
I15	135	38	M	Liver	Liver tissue	*	*	*	Normal	*	-	+,90%
J1	136	50	F	Liver	Cholangiocarcinoma	2	T3N1M0	IVA	Malignant	5	-	++,100%
J2	137	52	F	Liver	Cholangiocarcinoma	2	T3N1M0	IVA	Malignant	6.5	+,5%	+,70%
J3	138	62	M	Liver	Cholangiocarcinoma	2--3	T2aN0M0	II	Malignant	6	++,20%	++,90%
J4	139	60	F	Liver	Cholangiocarcinoma	2--3	T3N0M0	IIIA	Malignant	7	-	++,40%
J5	140	64	M	Liver	Cholangiocarcinoma with degeneration	3	T3N1M0	IVA	Malignant	9	-	+,10%
J6	141	68	M	Liver	Cholangiocarcinoma	3	T3N0M0	IIIA	Malignant	5	++,50%	++,90%
J7	142	68	M	Liver	Cholangiocarcinoma with necrosis	3	T3N0M0	IIIA	Malignant	7	++,20%	++,90%
J8	143	65	M	Liver	Cholangiocarcinoma	3	T3N0M0	IIIA	Malignant	7	-	+++,100%
J9	144	57	M	Liver	Cholangiocarcinoma	3	T3N0M0	IIIA	Malignant	9	-	++,70%
J10	145	51	M	Liver	Cholangiocarcinoma (degeneration)	3	T3N1M0	IVA	Malignant	*	*	*
J11	146	53	M	Liver	Cirrhosis	*	*	*	Cirrhosis	*	-	+,20%
J12	147	59	M	Liver	Cirrhosis	*	*	*	Cirrhosis	*	-	+,80%
J13	148	45	M	Liver	Cirrhosis	*	*	*	Cirrhosis	*	+,3%	++,90%
J14	149	23	M	Liver	Liver tissue	*	*	*	Normal	*	-	++,100%
J15	150	38	M	Liver	Liver tissue	*	*	*	Normal	*	+,1%	+,90%
_marker_

Find overlapping cases with this tissue array:

DLV1502

File Format: .xlsx

Release Date: 2025-01-17 15:53:45
Download

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
A	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
B	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
C	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
D	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
E	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
F	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
G	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
H	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
I	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
J	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	_ma

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
A	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
B	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
C	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
D	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
E	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
F	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
G	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
H	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
I	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
J	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	_ma

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
A	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
B	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
C	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
D	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
E	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
F	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
G	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
H	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
I	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
J	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	_ma